Today I start with a series of posts in which I will explain what I have called "puzzle pieces" that make up the H2020 puzzle for this last programming period 2018-2020.
In my previous post we discussed about how SME companies face R&D strategies, specially in regards will public aids from the European Commission. Lets try to bring some light about the strategy of “BIG” companies related to the same topic.
My name is Irene Baena. I’m a biologist, currently working as a R&I consultant at RTDI. I have always feel very concerned about how human beings interact with nature. As a specie, we have escaped from nature regulation and altered the “normal” evolution pace of other species. Our resource consumption and population growth is going so fast it will be practically impossible to maintain this scheme without suffering devastating consequences.
My name is Reyes Sansegundo Romero, Proposals Coordinator and R&I Consultant at RTDI. I have been working for more than 7 years in National, European and International research projects management. I have accompanied hundreds of researchers throughout the life cycle of their projects, from the conception of the idea to the start-up, justification and exploitation of the financed projects.
I start this blog with the goal of making private companies and research institutions realize how important it is for them to have a correct strategy, roadmap and understanding of EU public aid programs when they decide they want to take that route within their organizations. During many years I have been dealing with many mistakes and approaches to face these programs, being the most important one a wrong approach and perception about what this brings to the table.
The Bio-Based Industries Joint Undertaking (BBI JU) has published the annual work plan and budget for 2018. As we already saw the nature of the BBI JU and the hot topics in previous blog entrances, this time we will focus on the main aspects to be considered if you are interested in applying for this call.
The call considers four strategic orientations already set in previous years:
Within the current economic and societal European context, health research is crucial to ensure the continuing health and well-being of all European citizens.
The Horizon 2020 Advisory Group for Societal Challenge 1, "Health, Demographic Change and Well-being" has raised the following research priorities regarding health as a whole:
Reducing wastes production and transforming them into new high value products will be a transversal objective within the last H2020 period, especially present in the societal challenges related to Food security & Bioeconomy (SC2), Climate & Environment (SC5), and the Leadership in Enabling and Industrial Technologies - Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology (LEIT-NMBP). This objective falls under the focus area “Connecting economic and environmental gains – the Circular Economy”, which will count with €941 million budget.
Europe is getting older, it's hard but it's true. The European population is ageing rapidly; but living longer does not necessarily mean living healthier, more active and independent. The number of Europeans over 65 will double in the next 50 years, and the number of over 80's will almost triple. Life expectancy will continue to increase, yet unhealthy life years make up around 20% of a person's life.
Health is a fundamental aspect of quality of life, not only because being free from illness or injury directly affects our capacity to enjoy life, but also because health indirectly affects our capacity to produce and consume other valuable goods and services.
In the last centuries the relationship between human beings and forests has been based on the aggressive exploitation of their resources, without hardly taking into account the consequences.